Alzheimer’s drug sparks emotional battle as FDA nears deadline on whether to approve

The drug aducanumab would be the first new Alzheimer’s treatment since 2003, but it is also the latest example of a controversial medication that is passionately supported by patients and advocacy groups but has been rejected by the FDA’s outside advisers.

View original article
Contributor: Laurie McGinley